Polymeric nanoparticles and fluoropyrimidine platforms in targeted cancer therapy

Targeted cancer therapy has been significantly advanced by the development of polymeric nanoparticles and novel fluoropyrimidine platforms. Polymeric carriers offer controlled release, biocompatibility, and surface modification capabilities that enhance tumor-specific drug delivery while minimizing systemic toxicity. Fluoropyrimidines such as 5-fluorouracil (5-FU) have long been central to chemotherapeutic regimens, yet their therapeutic window is often limited by metabolic instability and resistance. Recent innovations in nanoscale formulation, including the synthesis of polymer-conjugated fluoropyrimidines like CF10, demonstrate improved pharmacokinetics, tumor uptake, and anti-proliferative efficacy in preclinical models. This review summarizes current advancements in polymeric nanocarriers for delivering fluoropyrimidine derivatives, discusses formulation strategies to overcome drug resistance, and highlights translational applications in gastrointestinal and gynecologic malignancies. Together, these approaches represent a promising direction in the design of next-generation chemotherapeutic systems.